DK2662094T3 - Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere - Google Patents
Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere Download PDFInfo
- Publication number
- DK2662094T3 DK2662094T3 DK13167148.9T DK13167148T DK2662094T3 DK 2662094 T3 DK2662094 T3 DK 2662094T3 DK 13167148 T DK13167148 T DK 13167148T DK 2662094 T3 DK2662094 T3 DK 2662094T3
- Authority
- DK
- Denmark
- Prior art keywords
- cylodextrin
- formulation
- proteasome inhibitors
- peptide proteasome
- complexation methods
- Prior art date
Links
- 229940079156 Proteasome inhibitor Drugs 0.000 title 1
- 238000010668 complexation reaction Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000003207 proteasome inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644122P | 2012-05-08 | 2012-05-08 | |
| US201361777475P | 2013-03-12 | 2013-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2662094T3 true DK2662094T3 (da) | 2024-07-08 |
Family
ID=48326170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13167148.9T DK2662094T3 (da) | 2012-05-08 | 2013-05-08 | Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10159746B2 (da) |
| EP (2) | EP2662094B1 (da) |
| JP (1) | JP6410264B2 (da) |
| KR (5) | KR20200130748A (da) |
| CN (2) | CN104411334A (da) |
| AU (2) | AU2013259573B2 (da) |
| CA (1) | CA2873044C (da) |
| CL (1) | CL2014003055A1 (da) |
| DK (1) | DK2662094T3 (da) |
| EA (1) | EA033614B1 (da) |
| ES (1) | ES2981576T3 (da) |
| FI (1) | FI2662094T3 (da) |
| HK (2) | HK1207827A1 (da) |
| HR (1) | HRP20240724T1 (da) |
| HU (1) | HUE066956T2 (da) |
| IL (1) | IL235553B (da) |
| LT (1) | LT2662094T (da) |
| MX (2) | MX364393B (da) |
| PL (1) | PL2662094T3 (da) |
| PT (1) | PT2662094T (da) |
| RS (1) | RS65647B1 (da) |
| SG (2) | SG11201407337QA (da) |
| SI (1) | SI2662094T1 (da) |
| SM (1) | SMT202400264T1 (da) |
| WO (1) | WO2013169897A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200130748A (ko) | 2012-05-08 | 2020-11-19 | 오닉스 세라퓨틱스, 인크. | 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법 |
| MX372671B (es) | 2013-07-19 | 2020-04-23 | Onyx Therapeutics Inc | Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres. |
| CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
| AR108919A1 (es) | 2016-06-29 | 2018-10-10 | Kezar Life Sciences | Proceso de preparación del inhibidor de inmunoproteasoma de péptido epoxicetona, y sus precursores |
| CA3029032C (en) | 2016-06-29 | 2024-10-29 | Kezar Life Sciences | CRYSTAL SALTS OF AN IMMUNOPROTEASOME PEPTIDE INHIBITOR EPOXYCETONE |
| WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
| JP7138103B2 (ja) | 2016-11-29 | 2022-09-15 | オキュリス エスエー | 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造 |
| JP7204670B2 (ja) * | 2017-05-03 | 2023-01-16 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | シクロデキストリン及びブスルファンを含有する組成物 |
| EP4670738A3 (en) | 2019-07-01 | 2026-03-04 | Oculis Operations Sàrl | Method for stabilizing the ph of an aqueous composition comprising a drug |
| CN110882221B (zh) * | 2019-11-29 | 2021-06-29 | 健进制药有限公司 | 一种注射用卡非佐米冻干制剂的生产工艺 |
| US20220304983A1 (en) * | 2020-04-09 | 2022-09-29 | Bika Biotech (Guangzhou) Co., Ltd | Bendamustine composition and use thereof |
| WO2022159319A2 (en) * | 2021-01-19 | 2022-07-28 | Mountain Valley Md Inc | A porous aluminum nanoparticulate structure |
| KR20260007821A (ko) * | 2024-07-08 | 2026-01-15 | (주) 에빅스젠 | 이마티닙을 포함하는 점안용 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4870060A (en) | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
| US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| DE19505263A1 (de) * | 1995-02-16 | 1996-08-22 | Consortium Elektrochem Ind | Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten |
| AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
| ES2257795T3 (es) | 1997-07-01 | 2006-08-01 | Pfizer Products Inc. | Procedimiento para producir una ciclodextrina. |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| ATE338564T1 (de) | 2000-10-12 | 2006-09-15 | Viromics Gmbh | Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen |
| JP2003063965A (ja) | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| RU2006127432A (ru) * | 2003-12-31 | 2008-02-10 | Сайдекс, Инк. (Us) | Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид, полученная из единичной дозы суспензии |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| WO2005105827A2 (en) | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
| HUE027850T2 (en) * | 2004-12-07 | 2016-11-28 | Onyx Therapeutics Inc | Preparation for proteasome inhibition |
| WO2007059507A2 (en) * | 2005-11-15 | 2007-05-24 | Baxter International, Inc. | Compositions comprising lipoxygenase inhibitors and cyclodextrin |
| KR20170040374A (ko) | 2007-10-04 | 2017-04-12 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| AU2009308516B2 (en) * | 2008-10-21 | 2016-08-25 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| WO2011133479A2 (en) | 2010-04-19 | 2011-10-27 | Niiki Pharma Inc. | Combination therapy with a proteasome inhibitor and a gallium complex |
| HK1211311A1 (en) | 2012-02-28 | 2016-05-20 | 锡德克斯药物公司 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| KR20200130748A (ko) | 2012-05-08 | 2020-11-19 | 오닉스 세라퓨틱스, 인크. | 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법 |
| PH12012502259A1 (en) | 2012-05-08 | 2019-07-03 | Onyx Therapeutics Inc | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
| WO2014066274A1 (en) | 2012-10-22 | 2014-05-01 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
-
2013
- 2013-05-08 KR KR1020207032107A patent/KR20200130748A/ko not_active Ceased
- 2013-05-08 EA EA201491994A patent/EA033614B1/ru not_active IP Right Cessation
- 2013-05-08 AU AU2013259573A patent/AU2013259573B2/en active Active
- 2013-05-08 PL PL13167148.9T patent/PL2662094T3/pl unknown
- 2013-05-08 WO PCT/US2013/040127 patent/WO2013169897A1/en not_active Ceased
- 2013-05-08 FI FIEP13167148.9T patent/FI2662094T3/fi active
- 2013-05-08 CN CN201380036466.0A patent/CN104411334A/zh active Pending
- 2013-05-08 CA CA2873044A patent/CA2873044C/en active Active
- 2013-05-08 KR KR1020197035904A patent/KR20190137963A/ko not_active Ceased
- 2013-05-08 SM SM20240264T patent/SMT202400264T1/it unknown
- 2013-05-08 SI SI201332084T patent/SI2662094T1/sl unknown
- 2013-05-08 KR KR1020227020311A patent/KR20220088949A/ko not_active Ceased
- 2013-05-08 SG SG11201407337QA patent/SG11201407337QA/en unknown
- 2013-05-08 HU HUE13167148A patent/HUE066956T2/hu unknown
- 2013-05-08 ES ES13167148T patent/ES2981576T3/es active Active
- 2013-05-08 KR KR1020147034238A patent/KR102054329B1/ko active Active
- 2013-05-08 US US14/399,582 patent/US10159746B2/en active Active
- 2013-05-08 MX MX2014013552A patent/MX364393B/es active IP Right Grant
- 2013-05-08 LT LTEP13167148.9T patent/LT2662094T/lt unknown
- 2013-05-08 CN CN201710866757.2A patent/CN107693772A/zh active Pending
- 2013-05-08 JP JP2015511660A patent/JP6410264B2/ja active Active
- 2013-05-08 HK HK15108517.0A patent/HK1207827A1/xx unknown
- 2013-05-08 HR HRP20240724TT patent/HRP20240724T1/hr unknown
- 2013-05-08 RS RS20240704A patent/RS65647B1/sr unknown
- 2013-05-08 PT PT131671489T patent/PT2662094T/pt unknown
- 2013-05-08 SG SG10201609318UA patent/SG10201609318UA/en unknown
- 2013-05-08 EP EP13167148.9A patent/EP2662094B1/en active Active
- 2013-05-08 KR KR1020247025639A patent/KR20240119191A/ko active Pending
- 2013-05-08 DK DK13167148.9T patent/DK2662094T3/da active
- 2013-05-08 EP EP24170493.1A patent/EP4410374A3/en active Pending
-
2014
- 2014-11-06 IL IL235553A patent/IL235553B/en active IP Right Grant
- 2014-11-07 MX MX2019004845A patent/MX2019004845A/es unknown
- 2014-11-10 CL CL2014003055A patent/CL2014003055A1/es unknown
-
2018
- 2018-01-19 AU AU2018200444A patent/AU2018200444B2/en active Active
- 2018-08-14 HK HK18110388.9A patent/HK1250927A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2662094T3 (da) | Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere | |
| SMT201700109B (it) | Inibitori di istone demetilasi | |
| DK2753334T3 (da) | Fap-aktiverede proteasomhæmmere til behandling af solide tumorer | |
| DK2841428T3 (da) | Dna-pk-inhibitorer | |
| DK3723369T3 (da) | Indretning til kortlægning af intraprædikationsmodus | |
| DK3777840T3 (da) | Rna-formulering til immunterapi | |
| HUE057264T2 (hu) | Eljárás új IDH1 inhibitorok elõállítására | |
| DK3454346T3 (da) | Anordning til cylotronfremstilling af technetium-99m | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| EP2877458A4 (en) | CYSTATHIONINE-Y-GAMMA-LYASE (CSE) -HEMMER | |
| DK3311834T3 (da) | Formulering til anti-alfa4beta7-antistof | |
| DK2518585T3 (da) | Termosifonanordninger til elektroniske enheder | |
| DK2804548T3 (da) | Apparat til okklusionsfjernelse | |
| LT2895484T (lt) | Gliukozilceramido sintazės inhibitoriai | |
| HUE036259T2 (hu) | Inhibitor vegyületek | |
| HUE037048T2 (hu) | Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására | |
| ZA201207384B (en) | Cylodextrin complexation methods for furmulating peptide proteasome inhibitors | |
| EP2877457A4 (en) | CYSTATHIONIN-LYASE (CSE) INHIBITORS | |
| EP2917210A4 (en) | KINASE INHIBITORS | |
| DK3300610T3 (da) | Fremgangsmåde til fraktionering af opløselige ærter | |
| DK2485011T3 (da) | Anordning til måling af afbøjningen af en genstand | |
| DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
| DK2849760T3 (da) | Fremgangsmåder til oligonukleotid-chelatkompleks | |
| EP2661633A4 (en) | PROOF OF PROTEOLYSIS | |
| EP2858975A4 (en) | FBXO3 INHIBITORS |